We conducted a retrospective study of breast cancer survivors to determine the risk factors for weight gain during endocrine therapy and the association of such weight gain with recurrence. Background: Weight gain is a negative prognostic factor in breast cancer (BC) patients. The risk factors for weight gain during adjuvant endocrine therapy (ET) and the extent to which such weight gain is associated with disease recurrence remain unclear. Patients and Methods: We retrospectively identified a cohort of women with a diagnosis of stage I-III, hormone receptorepositive, human epidermal growth factor receptor 2-negative BC from January 1997 to August 2008, who had received initial treatment at the MD Anderson Cancer Center, had completed 5 years of ET, and had remained free of locoregional or distant relapse or contralateral BC for ! 5 years after diagnosis. The weight change at the end of 5 years of ET was measured as the percentage of the change in weight from the start of ET, with a weight gain of > 5% considered clinically significant. Multivariable logistic regression and Cox proportional hazards models were used to assess the determinants of such weight gain and the risk of recurrence after 5 years. Results: Of 1282 long-term BC survivors, 432 (33.7%) had a weight gain of > 5% after 5 years of ET. Women who were premenopausal at diagnosis were 1.40 times more likely than women who were postmenopausal at diagnosis to have a weight gain of > 5%. Asian women had the lowest risk of gaining weight. The recurrence risks of patients who had gained weight and those who had not were not significantly different. Conclusion: Premenopausal BC patients had an increased risk of weight gain after 5 years of ET; however, BC patients with a weight gain of > 5% did not have an increased risk of disease recurrence.
Introduction
Weight gain is prevalent among breast cancer (BC) survivors, with 50% to 96% of survivors reporting weight gain after a diagnosis or during treatment of primary BC. [1] [2] [3] [4] [5] [6] [7] [8] Weight gain is considered to be a negative prognostic factor in BC patients. 9, 10 The public health implications of obesity and BC are immense. 11 Weight gain could possibly adversely affect survival among BC survivors, with an elevated risk of recurrence and mortality. [12] [13] [14] [15] [16] Although several studies have assessed weight gain in BC survivors, the causal factors underlying such weight gain remain elusive. However, possible explanations include fatigue, reduced physical activity, and increased caloric intake associated with behavioral or treatment-related factors. 17 Studies of the relationship between weight change and BC outcomes have yielded inconsistent findings. [18] [19] [20] [21] Different timings of the postdiagnostic weight change measures and the highly selected populations of patients with a good prognosis are also likely to have contributed to the varied findings. Most studies of weight gain in BC patients have assessed the weight change during or after adjuvant chemotherapy. 10, 22, 23 The predictors of weight gain after BC were analyzed in the Women's Healthy Eating and Living (WHEL) study, a prospective randomized clinical trial that included BC patients within 4 years of diagnosis with their weight recorded 1 year before the diagnosis, at study enrollment, and for a period of 6 years. The WHEL study reported an association of weight gain with chemotherapy, irrespective of the type or regimen. 23 In contrast, tamoxifen
was not significantly associated with weight gain. 23 Another study reported associations of weight gain after chemotherapy in patients with a younger age at diagnosis and with a premenopausal status, 24 supporting the idea that weight gain occurs with chemotherapy. However, the published data on weight gain determinants specifically during adjuvant endocrine therapy (ET) are very limited. The association of weight gain with BC recurrence is inconclusive. 14, 25, 26 A study that combined participants from the WHEL study and the Life after Cancer Epidemiology (LACE) study suggested that no increase in the risk of disease was present in the first 5 to 7 years after diagnosis in those with early-stage BC. 21 However, the weight change during ET was not specifically examined. Therefore, the objectives of our study were to identify the risk factors for weight gain specifically after 5 years of ET and to determine the extent to which such weight gain was associated with disease recurrence in long-term BC survivors.
Patients and Methods

Study Design and Patients
The present retrospective study was performed with approval of the MD Anderson Cancer Center's institutional review board (approval no. PA13-0424 . Menopausal status was recorded at the diagnosis and was defined as pre-, peri-, or postmenopausal by the attending physician using the guidelines that were current at that time. 29 Women who were perimenopausal were grouped with women who were premenopausal. We excluded patients who had received any treatment for BC before their initial visit to MD Anderson, those who had initiated ET > 1 year after their diagnosis, those who had received ET before their BC diagnosis (eg, for chemoprevention), those who had had any disease recurrence within 5 years of diagnosis, those with concurrent second primary cancers at any site, and those with missing demographic, tumor, and/or treatment details.
Outcomes of Interest
The 2 outcomes of interest for the present study were weight gain, specifically after 5 years of ET, and recurrence-free survival (RFS). The weight change percentages were calculated as [(weight after ET À weight before ET)/weight before ET] Â 100. A weight gain of > 5% was considered clinically relevant, because this cutoff has been reported in previous studies aiming to improve health outcomes among overweight and obese individuals [30] [31] [32] and because this value has been used to evaluate the effects of weight change in BC survivors. 19, 21, 23, 33, 34 We reviewed patients' medical records to verify their weight as assessed by direct measurement during clinic visits within 90 days of starting and ending ET. RFS was defined as the interval from diagnosis to any locoregional recurrence (including invasive ipsilateral tumor and invasive locoregional tumor) or distant recurrence or death from any cause. 35 Patients without recurrence were censored at their last follow-up visit.
Statistical Analysis
Univariate logistic regression analyses were used to evaluate the crude association between weight change and patients' demographic, clinical, and treatment characteristics. Variables with P values of < .25 on univariate analysis were included in a multivariable model. 36, 37 Backward selection criteria were used to retain variables in the multivariable model using a .05 significance level. Because of their clinical significance, chemotherapy, surgery, and ET were retained in the multivariable model, regardless of whether they had a P value of < .25 on univariate analysis. A log-rank test was used to compare the survival probabilities of patients with a weight gain of > 5% with those of patients with a weight change of 5%. A multivariable Cox proportional hazards regression model with adjustment for other baseline covariates was used to evaluate the association between weight gain and RFS. P < .05 was considered to indicate statistical significance. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC) and STATA, version 12 (StataCorp, College Station, TX).
Results
Patient Characteristics
The selection of the patient population is depicted in Figure 1 , and the patient characteristics are listed in Table 1 . The median follow-up time from the date of diagnosis was 11.2 years (quartile [Q] 1, 9.4 years; Q3, 13.3 years), and the median follow-up time from 5 years after diagnosis was 6.2 years (Q1, 4.4 years; Q3, 8.3 years). Of the 1282 long-term BC survivors included in the present study, 432 (33.7%) had a weight gain of > 5%, and 850 (66.3%) had a weight change of 5%. In both groups, w60% of patients were overweight or obese at diagnosis, and w40% of patients had a normal weight at diagnosis. Patients who had a weight gain of > 5% were younger than those with a weight change of 5%. Patients who had a weight gain of > 5% were also more likely to be e8 -Clinical Breast Cancer February 2018
Determinants of Weight Gain During Adjuvant ET premenopausal at diagnosis. Overall, the 2 groups had similar race distributions; however, the group of patients who gained weight had a lower proportion of Asian women. Patients with stage II or III disease or grade 3 tumors were more likely to have a weight gain of > 5% than were patients with stage I disease or grade 1 or 2 tumors. The tumor histology distribution did not differ significantly between the 2 groups. Compared with patients who had a weight change of 5%, patients with a weight gain of > 5% were more likely to have received chemotherapy, tamoxifen, or a sequential ET regimen and less likely to have received an aromatase inhibitor (AI). In terms of locoregional therapy, patients who had gained weight were more likely than patients who had not gained weight to have undergone mastectomy; however, the proportion of patients who had received radiation therapy did not differ between the 2 groups.
Univariate Analysis for Associations Between Patient Characteristics and Weight Change
The results of the univariate analysis are given in Table 2 . Premenopausal status, stage II or III disease, grade 3 tumor, and chemotherapy increased the likelihood of a weight gain of > 5%. Although both age and menopausal status at diagnosis were significantly associated with weight gain, owing to the high correlation between these 2 factors, 38 we decided to proceed with menopausal status only, because it plays a larger role than age in treatment decisions. 10 Compared with white women, AfricanAmerican women and Hispanic women were similarly more likely to gain weight, but Asian women were less likely to gain weight. Patients who received ET with an AI were less likely to gain weight than those who received tamoxifen. The BMI at diagnosis and radiation therapy were not associated with weight gain during ET.
Multivariable Analysis for Associations Between Patient Characteristics and Weight Change
The results of the multivariable analysis are listed in Table 3 . Women who were premenopausal at diagnosis were 1.40 times more likely than women who were postmenopausal at diagnosis to have a weight gain of > 5% (odds ratio, 1.40; 95% confidence interval, 1.01-1.93; P ¼ .040). Asian women were less likely than women of other races to gain weight. No tumor characteristics were associated with weight gain in the presence of other variables in the multivariable model. The odds of gaining weight did not differ significantly between patients who did or did not undergo chemotherapy or mastectomy. The specific type of ET agent (tamoxifen, AI, or sequential therapy) was not significantly associated with weight gain after 5 years of adjuvant ET.
Survival Analysis
Kaplan-Meier analysis revealed that, compared with women with a weight change of 5%, those with a weight gain of > 5% were not at an increased risk of recurrence after completing 5 years of ET (Figure 2 ). After adjustment for significant baseline risk factors and prespecified treatment variables, the multivariable Cox proportional hazards model showed that a weight gain of > 5% did not significantly increase the recurrence risk (hazard ratio, 0.95; 95% confidence interval, 0.62-1.47; P ¼ .829).
Discussion
The results of our study suggest that the risk of weight gain during ET is greater among BC patients who were premenopausal at diagnosis than among those who were postmenopausal. In addition, compared with those with a weight change of 5%, BC patients with a weight gain of > 5% during ET did not have a greater risk of disease recurrence. These findings help in understanding the relationship of weight gain specifically during ET and its implication on disease recurrence.
Previous studies have shown that premenopausal status at BC diagnosis is a strong predictor of weight gain, 10 although this association remains under discussion. [39] [40] [41] [42] [43] In our study, premenopausal status at diagnosis was associated with significant weight gain. Studies of BC patients receiving tamoxifen have found weight gain to be more highly correlated with premenopausal status than with postmenopausal status at diagnosis. 44 One study of women taking tamoxifen reported weight gain in 61% of premenopausal compared with 39% of postmenopausal women (P ¼ .0001). 45 A second study showed significant weight gain in patients receiving tamoxifen compared with no tamoxifen (P < .05), and this effect was more pronounced in premenopausal women. 46 A third study reported that the percentage of groups of BC survivors aged 49 years, 50 to 59 years, or ! 60 years at diagnosis who gained weight was 43%, 39%, and 33%, respectively, 47 all of which correlate with our findings. In the present study, the univariate analysis revealed that 
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Clinical Breast Cancer February 2018 -e9 both younger age and premenopausal status at diagnosis were significantly associated with a weight gain of > 5%. However, we included only menopausal status in the multivariable model, because it has a more important role in choosing a particular ET and age correlates with menopausal status. Differences in weight gain among race/ethnicity were also assessed. In our study, Asian women had a significantly lower risk of gaining weight during 5 years of ET compared with women of other races. Among women with BC from the WHEL study, AsianAmerican women had a smaller risk of weight gain with chemotherapy than did women of other races. 23 The correlation of race with weight gain suggests that demographic and genetic factors correlate with weight change in BC survivors and in the general population. 41 Although mastectomy did show an association with weight gain on univariate analysis, such an association did not hold in the multivariable analysis. Studies of younger BC patients who underwent mastectomy compared with older patients found that the younger women tended to have a worse body image. [48] [49] [50] [51] [52] [53] [54] [55] Others have shown that undergoing mastectomy might have an effect on 66 depending on the different clinical scenarios, such as becoming postmenopausal during ET or because of toxicities. As expected, patients receiving AIs were more likely to have been postmenopausal at diagnosis, and those receiving tamoxifen were more likely to have been premenopausal. However, we found no significant differences in weight change among patients receiving tamoxifen alone, an AI alone, or sequential therapy with tamoxifen and an AI. On univariate analysis, tamoxifen showed a correlation with weight gain but not on multivariable analysis. This could be because tamoxifen is essentially a surrogate for premenopausal status, which could be why it correlates with weight gain on univariate analysis. Our findings are similar to those reported in the published data. The ATAC (arimidex, tamoxifen, alone or in combination) trial, a large randomized study of early-stage postmenopausal BC, showed that 20% of patients receiving tamoxifen alone gained 2 to 5 kg, and 20.8% taking an AI alone had the same weight gain 67 during a period of 5 years of ET, implying that no difference was found in weight gain regarding the type of ET. Another randomized study of postmenopausal women who were disease free after 2 to 3 years of tamoxifen were randomly assigned to switch to exemestane or continue with tamoxifen until 5 years of treatment were completed. The study reported that 55.3% of patients receiving tamoxifen and 51.5% of patients receiving exemestane had a > 5% weight gain at 5 years. 2, 7 These weight gains were self-reported and did not have a fixed definition of weight gain, which complicates comparisons among the studies. It is noteworthy from these studies that weight gain is potentially not related to the type of ET but could result from more comprehensive reasons such as lifestyle factors, including diet, exercise routine, and sociodemographic characteristics, including age, marital status, education, and menopausal status. 68 Additional attributable reasons for weight gain due to an AI reported in a recent systemic analysis related it to a prevalent side effect of musculoskeletal pain due to AIs, leading to a decline in physical activity, 69 which, in turn, could contribute to energy imbalance. 4 In our study, patients with a weight gain of > 5% after 5 years of ET were not at an increased risk of recurrence. A similar result was reported combining the comparison cohort of the WHEL study and the LACE study, with no effect of weight gain after initial treatment on recurrence. 21 However, previous studies have identified weight gain as a risk factor for BC recurrence. 70, 71 In 1 of these studies, BMI gain was a significant determinant of recurrence (P ¼ .0008). 70 It would be difficult to compare these findings among studies because different measures were used to determine the weight change. Our study had the limitations inherent to a retrospective observational analysis, such as potential selections biases; however, because all BC survivors were disease free and had received ET for 5 years, we considered this to be a very homogeneous study population. Our study design was unique, because we decided to focus specifically on weight change during the 5 years of ET, and we did not consider the weight at or before the diagnosis. Therefore, some patients might have gained weight during their initial treatment (ie, surgery, chemotherapy, and radiation) before starting ET, which could complicate comparisons of our study results with those from other investigators studying weight gain after BC treatment. As a strength, our study included BC survivors for whom highly annotated clinicopathologic data were available, and we used very specific time points to determine the weight changes after ET.
Our findings suggest that, regardless of their baseline BMI or ET regimen, BC patients who are premenopausal at diagnosis have an increased risk of weight gain after 5 years of ET. Compared with patients with a weight change of 5% after ET, those with a weight gain of > 5% do not have an increased risk of BC recurrence. The findings of our study could be used to identify patients who might derive the most benefit from lifestyle interventions and specific weight management programs to help increase providers' and patients' awareness and knowledge of weight changes during BC treatment and its potential clinical implications. Counseling on lifestyle changes could be considered a health goal for premenopausal BC survivors and might help improve BC patients' enrollment in these weight management services. Weight management programs and clinical trials of health education materials, such as those offered at our institution, could also benefit premenopausal BC survivors. The associations between weight gain and BC prognosis might be more heterogeneous than previously reported, and future studies of weight gain among BC patients should focus on identifying the underlying biologic mechanisms of these associations.
Clinical Practice Points
The findings from the present study can help identify BC patients who might be at greater risk of gaining weight after 5 years of ET and who might derive the most benefit from lifestyle interventions and weight management programs. The present findings can also help increase providers' and patients' awareness and knowledge of weight changes during BC treatment and its potential clinical implications. The results of the present study might stimulate the development of practice tools and resources to help oncologists address weight change with their BC patients and help enroll them into weight management programs.
